Explore the words cloud of the AB-DiRecT project. It provides you a very rough idea of what is the project "AB-DiRecT" about.
The following table provides information about the project.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
|Coordinator Country||France [FR]|
|Total cost||3˙789˙717 €|
|EC max contribution||3˙429˙217 € (90%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-07-01 to 2021-06-30|
Take a look of project's partnership.
|1||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||coordinator||1˙234˙278.00|
|2||MEDIZINISCHE UNIVERSITAET WIEN||AT (WIEN)||participant||1˙116˙375.00|
|3||CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS||FR (POITIERS CEDEX)||participant||539˙188.00|
|4||INSERM - TRANSFERT SA||FR (PARIS)||participant||335˙625.00|
|5||CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS||FR (TOURS CEDEX 9)||participant||203˙750.00|
|6||GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.||UK (BRENTFORD)||participant||0.00|
Antimicrobial resistance imposes an important health and economic burden with the threat of a future without effective antibiotics requiring major changes to contemporary healthcare provision. Therefore, the discovery and development of novel mechanism of action agents able to treat resistant infections is a key urgent need. Gepotidacin is a first in class, novel triazaacenaphthylene antibacterial that is being developed by GSK. Due to its novel mechanism of action, gepotidacin is active in vitro against most target pathogens carrying resistance determinants to established antibacterials, including fluoroquinolones. Gepotidacin has broad gram-positive activity and selective gram-negative activity and is currently under development as a treatment for infections caused by N. gonorrhoeae (urogenital gonorrhoea) and E. coli (acute uncomplicated urinary tract infections), including isolates resistant to existing classes of antimicrobials. To explore the potential of gepotidacin to treat infections caused by N. gonorrhoeae or E. coli at other body sites, the AB-DiRecT consortium will conduct a tissue distribution study in tonsil and prostate after single oral dose of gepotidacin in healthy (non-infected) subjects undergoing elective tonsillectomy or prostatectomy. Microdialysis will be used to measure gepotidacin levels in tissue following surgery and PBPK, PopPK and PKPD models will be built to understand the tissue penetration of gepotidacin to characterize exposure response and to evaluate different dose regimens. Difference between infected and healthy tissue will be explored in an animal prostatitis infection model where gepotidacin PK in plasma and tissue will be determined using microdialysis. Overall the data generated in AB-DiRecT may support the potential for clinical trials to determine the efficacy of gepotidacin for the treatment for pharyngeal N. gonorrhoeae infections and / or prostatitis caused by E. coli.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AB-DIRECT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "AB-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More